Literature DB >> 19751402

Antibodies determine virulence in dengue.

Scott B Halstead1.   

Abstract

Four dengue viruses (DENV) cause syndromes that are self-limited or severe. The severe syndrome, dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), characterized by sudden vascular permeability, is not caused by inherently virulent DENV. This syndrome has consistently been observed to accompany dengue infections in individuals circulating heterotypic dengue antibodies at enhancing concentrations. In humans, dengue infections target monocytes/macrophages where, absent neutralization, heterotypic antibodies, perhaps directed at domain I-II of the envelope protein form immune complexes, attach to Fc receptors, suppress innate immunity, and increase productive infection. Diverse clinical responses to primary infections with different DENV strains do occur and occasionally result in subclinical vascular permeability observed as hypovolemia. The fact that American (AM) genotype DENV 2 produce only mild disease during secondary dengue infections is best explained by the downregulation of disease by DENV 1 antibodies directed at a unique antigenic structure expressed on AM DENV 2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19751402     DOI: 10.1111/j.1749-6632.2009.05052.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

Review 1.  IgG Fc Glycosylation in Human Immunity.

Authors:  Taia T Wang
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

2.  A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Kari Opert; Adrienne P Jarvis; Beulah P Sabundayo; Benjamin D McElvany; Eli A Sendra; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2016-02-16       Impact factor: 5.226

3.  Virus antibody dynamics in primary and secondary dengue infections.

Authors:  Tanvi P Gujarati; G Ambika
Journal:  J Math Biol       Date:  2014-01-04       Impact factor: 2.259

4.  Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Authors:  Beth D Kirkpatrick; Anna P Durbin; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Sean A Diehl; Dan Elwood; Adrienne P Jarvis; Beulah P Sabundayo; Caroline E Lyon; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Steven S Whitehead
Journal:  J Infect Dis       Date:  2015-03-22       Impact factor: 5.226

Review 5.  The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Authors:  Beth-Ann G Coller; David E Clements; Andrew J Bett; Sangeetha L Sagar; Jan H Ter Meulen
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

6.  Endothelial cells elicit immune-enhancing responses to dengue virus infection.

Authors:  Nadine A Dalrymple; Erich R Mackow
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

7.  Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase.

Authors:  Chelsea M Byrd; Douglas W Grosenbach; Aklile Berhanu; Dongcheng Dai; Kevin F Jones; Kara B Cardwell; Christine Schneider; Guang Yang; Shanthakumar Tyavanagimatt; Chris Harver; Kristin A Wineinger; Jessica Page; Eric Stavale; Melialani A Stone; Kathleen P Fuller; Candace Lovejoy; Janet M Leeds; Dennis E Hruby; Robert Jordan
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

Review 8.  Dengue vaccines: recent developments, ongoing challenges and current candidates.

Authors:  Monica A McArthur; Marcelo B Sztein; Robert Edelman
Journal:  Expert Rev Vaccines       Date:  2013-08       Impact factor: 5.217

9.  Convergent antibody signatures in human dengue.

Authors:  Poornima Parameswaran; Yi Liu; Krishna M Roskin; Katherine K L Jackson; Vaishali P Dixit; Ji-Yeun Lee; Karen L Artiles; Simona Zompi; Maria José Vargas; Birgitte B Simen; Bozena Hanczaruk; Kim R McGowan; Muhammad A Tariq; Nader Pourmand; Daphne Koller; Angel Balmaseda; Scott D Boyd; Eva Harris; Andrew Z Fire
Journal:  Cell Host Microbe       Date:  2013-06-12       Impact factor: 21.023

10.  Seroprevalence of dengue infection in pregnant women and placental antibody transfer.

Authors:  Zinia T Nujum; N Saritha; M R Prathibha Raj; A V Gayathri; C Nirmala; K Vijayakumar; Sara Varghese
Journal:  Med J Armed Forces India       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.